{
  "id": "adv_mhgap#management_e1f1cfad",
  "content": "anticholinergic medications.\nTRIHEXYPHENIDYL Start 1 mg daily. Rarely, angle-closure glaucoma, myasthenia gravis and\n(Benzhexol) Increase to 4-12 mg per day in 3-4 divided doses gastrointestinal obstruction.\n(maximum 20 mg daily).\nRoute: p.o\nTABLE 3: Mood stabilizers\nAvoid in women who are pregnant or breastfeeding if possible.\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nLITHIUM Start 300 mg daily. Increase gradually every Common: sedation, cognitive problems, tremor, : Contraindicated in patients with: severe cardiac or kidney disease.\n7 days until target blood level reached (maximum impaired coordination, hypotension, leukocytosis,\nDehydration can increase lithium levels.\n600-1200 mg daily). Monitor every 2-3 months. polyuria, polydipsia, nausea, diarrhea, weight gain, hair\nUse only if clinical\nRoute: p.o loss, rash. Drug-drug interactions: nonsteroidal anti-inflammatory drugs (NSAIDs),\nand laboratory monitoring angiotensin-converting-enzyme inhibitor (ACE inhibitor), thiazide diuretics,\nTarget blood levels: 0.6-1.0 mEq/liter Serious: diabetes insipidus, hypothyroidism,\nare available. metronidazole, and tetracycline can increase lithium levels.\n– In acute manic episode: 0.8-1.0 mEq/liter ECG changes (arrhythmia, sick sinus syndrome,\n– For maintenance treatment: 0.6-0.8 mEq/liter. T-wave changes). Lithium toxicity can cause seizures, delirium, coma, and death.\n6 months on medication is needed to determine full\neffectiveness of maintenance treatment.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "stress",
      "emotions",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Management anticholinergic medications.\nTRIHEXYPHENIDYL Start 1 mg daily. Rarely, angle-closure glaucoma, myasthenia gravis and\n(Benzhexol) Increase to 4-12 mg per day in 3-4 divided doses gastrointestinal obstruction.\n(maximum 20 mg daily).\nRoute: p.o\nTABLE 3: Mood stabilizers\nAvoid in women who are pregnant or breastfeeding if possible.\nMEDICATION DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nLITHIUM Start 300 mg daily. Increase gradually every Common: sedation, cognitive problems, tremor, : Contraindicated in patients with: severe cardiac or kidney disease.\n7 days until target blood level reached (maximum impaired coordination, hypotension, leukocytosis,\nDehydration can increase lithium levels.\n600-1200 mg daily). Monitor every 2-3 months. polyuria, polydipsia, nausea, diarrhea, weight gain, hair\nUse only if clinical\nRoute: p.o loss, rash. Drug-drug interactions: nonsteroidal anti-inflammatory drugs (NSAIDs),\nand laboratory monitoring angiotensin-converting-enzyme inhibitor (ACE inhibitor), thiazide diuretics,\nTarget blood levels: 0.6-1.0 mEq/liter Serious: diabetes insipidus, hypothyroidism,\nare available. metronidazole, and tetracycline can increase lithium levels.\n– In acute manic episode: 0.8-1.0 mEq/liter ECG changes (arrhythmia, sick sinus syndrome,\n– For maintenance treatment: 0.6-0.8 mEq/liter. T-wave changes). Lithium toxicity can cause seizures, delirium, coma, and death.\n6 months on medication is needed to determine full\neffectiveness of maintenance treatment. Anticholinergic medications. trihexyphenidyl start 1 mg daily."
}